ImmunityBio, Inc. IBRX
Set alert
At close · Oct 30
After hours · Oct 30, 7:55 PM ET
- YTD
- +318.69%
- 1 year
- +251.27%
- Open
- 8.48
- Prev close
- 8.74
- Mkt cap
- 8.79B
- Vol
- 8.96M
- Avg vol
- 11.49M
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.12
- High
- 8.72
- Forward P/E
- -113.05
- Beta
- 0.03
- Short ratio
- 7.96
- Inst. own
- 19.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.70
- 200-d avg
- 7.88
- 1y target
- 14.25
5D chart
Signals (109)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:50 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:20 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:20 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:05 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:50 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| RSI: Oversold | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:25 AM | 6 days ago |
News
5 days ago benzinga.com
Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original
Jim Cramer called ImmunityBio a strong speculative buy, favored Monster over Celsius, avoided USA Rare Earth and liked Glacier Bancorp.
5 days ago defenseworld.net
ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC
Davidson Kahn Capital Management LLC lessened its stake in ImmunityBio, Inc. (NASDAQ: IBRX) by 50.9% during the third quarter, according to its most recent filing with the Securities and Exchange…
-
1 week ago benzinga.com
ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
-
1 week ago benzinga.com
ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle…
1 week ago businesswire.com
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its…
1 week ago benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
1 week ago benzinga.com
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
A recent study published in the Journal of Urology revealed promising long-term results for ImmunityBio, Inc. (NASDAQ:IBRX) and its immunotherapy treatment, ANKTIVA.
1 week ago benzinga.com
ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.
-
2 weeks ago benzinga.com
ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The…
2 weeks ago businesswire.com
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032…
2 weeks ago zacks.com
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
IBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.
-
2 weeks ago benzinga.com
Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.
2 weeks ago benzinga.com
ImmunityBio Stock Climbs Thursday: What's Going On?
ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Thursday after the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive…
2 weeks ago benzinga.com
ImmunityBio Stock Climbs Thursday: What's Going On?
ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
2 weeks ago businesswire.com
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the…
2 weeks ago benzinga.com
Why Is ImmunityBio Stock Gaining Wednesday?
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
3 weeks ago defenseworld.net
ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
3 weeks ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago benzinga.com
Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaffirmed FY26 EPS guidance.
3 weeks ago gurufocus.com
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Ch
3 weeks ago businesswire.com
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and…
3 weeks ago defenseworld.net
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has…
1 month ago benzinga.com
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
1 month ago benzinga.com
ImmunityBio Stock Jumps: What's Going On?
ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.
1 month ago defenseworld.net
State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX
State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange…
1 month ago zacks.com
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
1 month ago defenseworld.net
Tidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRX
Tidal Investments LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
1 month ago defenseworld.net
ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven research firms that are presently covering the stock, Marketbeat Ratings reports.…
1 month ago zacks.com
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?
1 month ago seekingalpha.com
ImmunityBio: None Of The Moonshots Is Priced In
ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and significant pipeline expansion potential. Current valuation reflects success in bladder cancer and…
2 months ago defenseworld.net
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX
Canada Pension Plan Investment Board acquired a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) during the undefined quarter, according to the company in its most recent Form 13F filing…
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago gurufocus.com
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer and Check
-
2 months ago benzinga.com
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10)…
3 months ago benzinga.com
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug
ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding treatment options for NMIBC and NSCLC.
-
3 months ago benzinga.com
Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients
The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to…
3 months ago benzinga.com
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now.
4 months ago benzinga.com
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'
Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun concept, also likes Trulieve Cannabis (TRLV) and advised holding onto Ashland (ASH).
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
-
5 months ago benzinga.com
ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc. ((
-
5 months ago benzinga.com
ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder
ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating that ANKTIVA® (nogapendekin alfa…
-
5 months ago benzinga.com
ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia,…
5 months ago benzinga.com
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
5 months ago benzinga.com
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug
ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data showing durable bladder cancer outcomes.
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $15 price target.
-
5 months ago benzinga.com
Reported Earlier, ImmunityBio Says FDA Accepted ANKTIVA Plus Bacillus Calmette-Guerin Filing For Papillary Non-Muscle Invasive Bladder Cancer Following Workshop Support And National Comprehensive Cancer Network Guidance
Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC with papillary diseaseFDA noted in its filing communication that the supplemental BLA accepted for…
5 months ago benzinga.com
ImmunityBio Says ANKTIVA Combo Outperformed Rival Bladder Cancer Therapies
ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key bladder cancer measures.
-
5 months ago benzinga.com
ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG
NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a complete response (CR) at any point of the study versus nadofaragene firadenovec-vncg in…
5 months ago benzinga.com
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership
ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end a decade-long U.S. supply shortage.